Skip to main content
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. — Investor Relations & Filings

Ticker · MLYS ISIN · US6031701013 US Manufacturing
Filings indexed 312 across all filing types
Latest filing 2026-05-06 Interim / Quarterly Rep…
Country US United States of America
Listing US MLYS

About Mineralys Therapeutics, Inc.

https://mineralystx.com/

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The company's primary goal is to improve outcomes for individuals managing hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other related cardio-renal metabolic diseases. Mineralys aims to provide a targeted approach to treatment, addressing the underlying hormonal causes of these conditions to redefine disease management and move beyond traditional trial-and-failure therapeutic strategies.

Recent filings

Filing Released Lang Actions
10-Q - Mineralys Therapeutics, Inc. (0001933414) (Filer)
Interim / Quarterly Report
2026-05-06 English
8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
Regulatory Filings
2026-05-06 English
ARS - Mineralys Therapeutics, Inc. (0001933414) (Filer)
Annual Report
2026-04-10 English
DEF 14A - Mineralys Therapeutics, Inc. (0001933414) (Filer)
Proxy Solicitation & Information Statement
2026-04-08 English
4 - MINERALYS THERAPEUTICS, INC. (0001933414) (Filer)
Director's Dealing
2026-02-20 English
4 - MINERALYS THERAPEUTICS, INC. (0001933414) (Filer)
Director's Dealing
2026-02-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.